Opioid receptor antagonists

General pharmacodynamics of the group

Opioid receptor antagonists have the specific ability to block $\mu$-, $\delta$-, and $\kappa$-receptors of the nervous system. Their main pharmacological value lies in the fact that they effectively eliminate clinical manifestations caused by the intake of narcotic analgesics.

When drugs of this group are administered, the following opioid effects are reversed in the patient:

• Analgesia (pain relief);
• Euphoria (pathologically elevated mood);
• Respiratory depression (the most dangerous side effect of opioids);
• Sedation and miosis (pupillary constriction).

Naloxone: emergency care medication

According to its chemical structure, naloxone is a phenanthrene derivative. In clinical practice, it acts as a full competitive antagonist of opioid receptors.

• Main indication: Acute intoxication (overdose) with narcotic analgesics. The drug competitively displaces opioid molecules from binding to the respiratory center receptors, restoring adequate breathing.
• Pharmacokinetics: Administered primarily intravenously for the fastest possible effect. It is characterized by a relatively short half-life—from 2 to 4 hours.
• Spectrum of activity: Successfully relieves overdose symptoms caused by both "pure" agonists and drugs with agonist-antagonist properties.
• Important feature: Naloxone demonstrates clinically reduced efficacy in reversing buprenorphine overdose. This is because buprenorphine forms an exceptionally strong bond with opioid receptors that is difficult to break even with high doses of the antagonist.

Naltrexone: baseline therapy for dependencies

Unlike naloxone, naltrexone has a pronounced prolonged action and is used for scheduled treatment in addiction medicine.

• Pharmacokinetics: The drug is highly effective when taken orally (by mouth). The duration of its therapeutic effect lasts up to 24 hours.
• Treatment of substance use disorder: By reliably blocking receptors, naltrexone completely prevents the development of euphoria from taking any opioids. The patient stops getting "pleasure" from the drug, which contributes to the extinction of the dependence.
• Treatment of alcoholism: The drug is also actively used for the treatment of alcohol dependence, as it reliably reduces the craving for alcohol consumption.
• Side effects: Prescribing naltrexone to patients with already established physical drug dependence (prior to detoxification) inevitably triggers the development of acute withdrawal syndrome (abstinence).

Differential diagnosis of the groups

In pharmacology, it is critically important to distinguish pure antagonists from other groups of drugs that interact with opioid receptors. A clear distinction should be made between:

1. Pure antagonists (naloxone, naltrexone) — block receptors without causing intrinsic activation effects.
2. Agonists-antagonists (e.g., nalbuphine) — stimulate certain types of opioid receptors and block others, possessing their own analgesic potential.
3. Full agonists (e.g., Omnopon) — classical drugs that fully stimulate receptors and cause the entire spectrum of opioid effects, including dependence.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Features of the strong binding of buprenorphine to opioid receptors.
• The mechanism of competitive displacement of opioids from the respiratory center of the medulla oblongata.
• Pathogenesis of the development of withdrawal syndrome upon administration of antagonists to dependent individuals.
• Pharmacological profile and effects of full agonists using Omnopon as an example.
• Comparative characteristics of pure antagonists and agonists-antagonists (nalbuphine).

Other topics in the "Analgesics" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.